Psychedelic Therapy

By the Editorial Team · Wednesday, September 23, 2026

Advocates are urging the federal government to establish standardized regulations for psychedelic-assisted therapies to ensure their safe and effective use within U.S. healthcare. This push responds to growing mental health needs and concerns over unregulated treatments sought outside licensed medical settings, highlighting the importance of integrating these therapies under FDA guidelines.

Concerns over the unregulated use of psychedelic-assisted therapies have prompted calls for the establishment of federal standards to ensure their safe integration into the U.S. healthcare system. Advocates emphasize the urgent need for regulatory oversight amid growing interest in these treatments, particularly among populations facing significant mental health challenges.

Jon Kostas, executive director of the Association for Prescription Psychedelics, highlighted the risks associated with seeking psychedelic therapies outside of accredited medical settings. In a recent letter, Kostas pointed to the United States’ escalating mental health crisis, affecting veterans, terminally ill patients, minority groups, and others, which has driven some individuals to pursue treatments abroad from unlicensed providers.

Kostas, who participated as the first subject in a New York University clinical trial investigating psilocybin-assisted therapy for alcohol-use disorder, described his experience as life-saving. He underscored that psychedelic drugs must be administered by trained and licensed medical professionals within regulated facilities to guarantee patient safety.

The call for action aligns with a presidential executive order issued in April under the previous administration aimed at accelerating the development of psychedelic medicine. Kostas argued that this directive presents an opportunity for federal agencies to collaborate and establish clear guidelines to incorporate these therapies within the framework of existing Food and Drug Administration (FDA) regulations.

While proponents recognize the potential benefits of psychedelic therapies, they stress the importance of ensuring treatments are both efficacious and safe before broader application. The growing interest in psychedelics, combined with the current gaps in regulatory oversight, has raised concerns about the variability in treatment quality and patient outcomes.

As government agencies and medical entities explore pathways to integrate psychedelic medicines into conventional care, voices like Kostas’ advocate for a balance between innovation and caution. An emphasis on federally approved protocols and professional administration aims to protect patients and support the responsible advancement of psychedelic-assisted therapies in the United States.

This article was reported by synthesizing coverage from multiple independent news outlets to present a balanced, unbiased account. Read about our editorial standards. Spotted an error? Let us know.